Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1366908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Xiao Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China. Hauptthemen laut MEDLINE: Metagenomics, High-Throughput Nucleotide Sequencing, Febrile Neutropenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metagenomic next-generation sequencing (mNGS) is a novel non-invasive and comprehensive technique for etiological diagnosis of infectious diseases. However, its practical significance has been seldom reported in the context of hematological patients with high-risk febrile neutropenia, a unique patient group characterized by neutropenia and compromised immune responses.
Methods
This retrospective study evaluated the results of plasma cfDNA sequencing in 164 hematological patients with high-risk febrile neutropenia. We assessed the diagnostic efficacy and clinical impact of mNGS, comparing it with conventional microbiological tests. Results mNGS identified 68 different pathogens in 111 patients, whereas conventional methods detected only 17 pathogen types in 36 patients. mNGS exhibited a significantly higher positive detection rate than conventional methods (67.7% vs . 22.0%, P < 0.001). This improvement was consistent across bacterial (30.5% vs . 9.1%), fungal (19.5% vs . 4.3%), and viral (37.2% vs . 9.1%) infections ( P < 0.001 for all comparisons). The anti-infective treatment strategies were adjusted for 51.2% (84/164) of the patients based on the mNGS results. Conclusions mNGS of plasma cfDNA offers substantial promise for the early detection of pathogens and the timely optimization of anti-infective therapies in hematological patients with high-risk febrile neutropenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China.
- School of Pharmacy, Chengdu Medical College, Chengdu, China.
- Department of Pharmacy, Chengdu Eighth People's Hospital, Chengdu, China.
Zitieren
APA
Wang, X., Zhang, H., Zhang, N., Zhang, S., Shuai, Y., Miao, X., Liu, Y., Qiu, L., Ren, S., Lai, S., Han, Y., Yao, H., Zhang, X., Fan, F., Sun, H., & Yi, H. (2024). Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1366908
Vancouver
Wang X, Zhang H, Zhang N, Zhang S, Shuai Y, Miao X, et al. Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1366908
BibTeX
@article{Wang2024,
author = {Wang, Xiao and Zhang, Huiye and Zhang, Nan and Zhang, Shan and Shuai, Yanrong and Miao, Xiaojuan and Liu, Yilan and Qiu, Ling and Ren, Shihui and Lai, Sihan and Han, Ying and Yao, Hao and Zhang, Xupai and Fan, Fangyi and Sun, Haoping and Yi, Hai},
title = {Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1366908}
}
EUVIMED